ReviewMicroorganisms2023
The Challenge of Overcoming Antibiotic Resistance in Carbapenem-Resistant Gram-Negative Bacteria: "Attack on Titan".
Review in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Carbapenem-resistantPublic health in practice (Oxford, England) · 2026Review
- Development of an mRNA vaccine against the OprF ofMicrobiology spectrum · 2026Article
- Comparative effectiveness and safety of aztreonam-avibactam or ceftazidime-avibactam plus aztreonam versus best available therapy for severe gram-negative infections: a systematic review, meta-analysis, and trial sequential analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Targeting histidine biosynthesis in Acinetobacter baumannii: structure-based discovery of natural inhibitors of ATP-phosphoribosyltransferase.Molecular diversity · 2026Article
- Genomic architecture of fourth-generation cephalosporin-resistant Klebsiella pneumoniae Species Complex (KpSC) from patients and their hospital environment in Uganda.BMC microbiology · 2026Article
- Comprehensive Evaluation of Uropathogens' AMR in a Romanian Tertiary Center: Male vs. Female Comparison.Microorganisms · 2026Article
- Multiplex PCR-Based Detection of Eight Carbapenemase Genes and Their Clinical Characteristics in Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2026Article
- Dietary Spirulina platensis phycocyanin enhances growth performance, antioxidant status, and immune-related gene expression in Japanese quails (Coturnix japonica).Scientific reports · 2026Article
- Recurrent infections caused by ESBL-producing enterobacterales with or without subsequent development of distinct carbapenem-resistant phenotypes: differential driving factors and impact on outcome.JAC-antimicrobial resistance · 2026Article
- Whole genome analysis of carbapenem resistantNew microbes and new infections · 2026Article
- Clinical distribution and drug resistance of carbapenem-resistant Pseudomonas aeruginosa infection in Eastern China from 2019 to 2024.BMC infectious diseases · 2026Article
- ANIA: an inception-attention network for predicting minimum inhibitory concentration of antimicrobial peptides.Briefings in bioinformatics · 2026Article
- Genomic characterisation and antimicrobial resistance ofFrontiers in cellular and infection microbiology · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Integrating clinical data into evidence-based practice: institutional guideline development for diabetic foot infections.Frontiers in endocrinology · 2026Article
- From Laboratory to Clinic: Translational Medicine Paradigm of Polymyxin B Nanopreparations for Overcoming Drug-Resistant Bacterial Infections.International journal of nanomedicine · 2026Review
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global burden of bacterial resistance remains one of the most serious public health concerns. Infections caused by multidrug-resistant (MDR) bacteria in critically ill patients require immediate empirical treatment, which may not only be ineffective due to the resistance of MDR bacteria to multiple classes of antibiotics, but may also contribute to the selection and spread of antimicrobial resistance. Both the WHO and the ECDC consider carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.